Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 19/20 | 1.00 |
| ▸ | PIM1 | P11309 | 18/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947843 | 0.95 | PIM2 (0.90) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079484 | 0.90 | PIM2 (0.81) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079560 | 0.90 | PIM2 (0.81) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079366 | 0.88 | PIM2 (0.79) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079130 | 0.88 | PIM2 (0.79) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12079758 | 0.88 | PIM2 (0.78) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12080005 | 0.88 | PIM2 (0.78) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL15947839 | 0.88 | PIM2 (0.78) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12080567 | 0.86 | CYP3A4 (1.00) | PIM2PIM1PIM3CYP3A4CYP2D6 | |
| SCHEMBL12080355 | 0.86 | CYP3A4 (1.00) | PIM2PIM1PIM3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.